Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma

Karla Hahn, Javier F. Magrina, Byron J. Masterson

Research output: Contribution to journalArticlepeer-review

Abstract

A review of 18 patients with Stage III epithelial ovarian carcinoma treated by surgery and followed by cyclophosphamide and cisplatinum combination chemotherapy is presented. At the end of 12 months from the initiation of chemotherapy, 88.9% of the patients were alive and 77.8% remained free of tumor progression. At the end of 2 years 77.8% of the patients were alive and 44.4% of the patients were free of tumor progression. The combination of cyclophosphamide and cisplatinum has low toxicity, a simple pattern of administration, and has provided satisfactory results.

Original languageEnglish (US)
Pages (from-to)509-513
Number of pages5
JournalInternational Journal of Gynecology and Obstetrics
Volume23
Issue number6
DOIs
StatePublished - Dec 1985

Keywords

  • Chemotherapy
  • Cyclophosphamide and cisplatinum combination
  • Epethelial ovarian carcinoma
  • Free tumor progression
  • Low toxicity
  • Simple pattern of administration

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma'. Together they form a unique fingerprint.

Cite this